FDA advisory panel votes to recommend rivaroxaban, the first serious contender to oral blood...

|By:, SA News Editor

FDA advisory panel votes to recommend rivaroxaban, the first serious contender to oral blood clot treatment warfarin in decades. Johnson & Johnson (JNJ) has applied for use to treat orthapedic surgery patients, but Act II - stroke prevention - will be far more lucrative.